This is a competitive renewal for our longstanding Training Program in Diabetes, Endocrinology and Metabolic Diseases. During the most recent funding cycle, 4 postdoctoral fellows were supported each year. A total of 11 trainees working in 9 different labs have been supported. The program is designed to accommodate both Ph.D. scientists as well as physician scientists with M.D. or M.D, Ph.D. degrees, of whom most enter through the Penn Clinical Fellowship Program in Endocrinology, Diabetes and Metabolism. Of the postdoctoral trainees supported by this T32 during the last 4 years who are no longer in training, one has a staff position at Merck, two have junior faculty positions at University of Pennsylvania and Long Island Jewish/Hofstra University, respectively and one is in private practice in an academic environment. For the next period, we request additional support to add one more fellow. We also request, for the first time, sufficient funds to support three predoctoral students working in the areas of this program during their third through fifth years of graduate school. At present, there are in laboratories directed by our trainers 29 students working towards their Ph.D. theses, the majority focusing on problems relevant to the mission of this T32 and unsupported by a training grants. Five (26%) are underrepresented minorities. Our 24 training faculty have primary appointments in seven Medical School Departments and consist of 14 professors, 7 associate professors, and assistant 3 professors. Six members of the training faculty are woman and one is African-American. In the last two funding cycles, six faculty members have been removed from the grant and twelve have been appointed to the training grant. Training grant faculty bring to the program expertise in 2-cell development and function, hormone action, physiology, diabetic complications, genetics in humans and model organisms, transcriptional regulation, patient oriented research, epidemiology and biostatistics. This training program continues to provide superb preparation for those scientists committed to careers in research into diabetes, endocrinology and metabolism.
Obesity and diabetes mellitus are reaching epidemic proportions worldwide. In the United States alone, the estimated cost of diabetes in 2007 was $174 billion, including $116 billion in excess medical expenditures and $58 billion in reduced national productivity. The goal of this grant is to help train the next generation physician and basic researchers at the predoctoral and doctoral levels in research into the prevention and treatment of diabetes and other endocrine disorders.
|Garin, Margaret C; Arnold, Alice M; Lee, Jennifer S et al. (2014) Subclinical hypothyroidism, weight change, and body composition in the elderly: the Cardiovascular Health Study. J Clin Endocrinol Metab 99:1220-6|
|Garin, Margaret C; Arnold, Alice M; Lee, Jennifer S et al. (2014) Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. J Clin Endocrinol Metab 99:2657-64|
|Metzger, David E; Liu, Chengyang; Ziaie, Amin Sam et al. (2014) Grg3/TLE3 and Grg1/TLE1 induce monohormonal pancreatic ?-cells while repressing ?-cell functions. Diabetes 63:1804-16|
|Avrahami, Dana; Li, Changhong; Yu, Ming et al. (2014) Targeting the cell cycle inhibitor p57Kip2 promotes adult human ? cell replication. J Clin Invest 124:670-4|
|Fishbein, Lauren; Merrill, Shana; Fraker, Douglas L et al. (2013) Inherited mutations in pheochromocytoma and paraganglioma: why all patients should be offered genetic testing. Ann Surg Oncol 20:1444-50|
|Garin, Margaret C; Burns, Carrie M; Kaul, Shailja et al. (2013) Clinical review: The human experience with ghrelin administration. J Clin Endocrinol Metab 98:1826-37|
|Metzger, David E; Gasperowicz, Malgorzata; Otto, Florian et al. (2012) The transcriptional co-repressor Grg3/Tle3 promotes pancreatic endocrine progenitor delamination and ?-cell differentiation. Development 139:1447-56|
|Lu, Mingjian; Wan, Min; Leavens, Karla F et al. (2012) Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med 18:388-95|
|Fishbein, Lauren; Nathanson, Katherine L (2012) Pheochromocytoma and paraganglioma: understanding the complexities of the genetic background. Cancer Genet 205:1-11|
|Parsons, Ronald F; Yu, Ming; Vivek, Kumar et al. (2012) Murine islet allograft tolerance upon blockade of the B-lymphocyte stimulator, BLyS/BAFF. Transplantation 93:676-85|
Showing the most recent 10 out of 44 publications